Biogen to buy China rights to immune disease drug (BIIB)
Summary
Biogen (BIIB) stock is in focus as the company inks a deal worth up to $850M with TJ Bio to buy Greater China rights to felzartamab, an antibody drug. Read more...
Description
Biogen (BIIB) stock is in focus as the company inks a deal worth up to $850M with TJ Bio to buy Greater China rights to felzartamab, an antibody drug. Read more...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source